The adjunction of the BETi JQ1 to immune-stimulating therapies (anti-PD-1 or anti-CD137 antibodies) improved Eμ-Myc lymphoma-bearing mice's survival [38]. This evidence concerns the gene TNFRSF9 and lymphoma.